Juzi Bioscience's performance in the third quarter meets expectations, approaching the previously provided guidance for the second half of the year. Management expressed confidence in achieving the full-year guidance.
According to the Securities Times app, China Merchants Securities released a research report stating that it maintains a 'shareholding' rating on Juzi Bioscience (02367). The forward-looking P/E ratio from the middle of 2025 to the end of 2025 remains at 25, and the target price has been raised from the original HK$53 to HK$60, corresponding to a forecasted P/E ratio of 22 times for 2025. The company's profit outlook is stable, maintaining the current profit forecast from 2024 to 2026.
Based on recent company roadshows, G-biopharma's overall performance in the third quarter meets expectations, approaching the guidance given earlier for the second half of the year. Management has expressed confidence in meeting the full-year guidance. In terms of channels, online performance is better than offline. As the third quarter is typically a low season for the cosmetic industry, the entire quarter is mainly preparation for Singles' Day sales. This year's Singles' Day activities have been extended overall, and preliminary data shows impressive company performance. The sales deposit situation of leading anchors is as expected.
